VHL Gene Mutations in Renal Cell Carcinoma: Role as a Biomarker of Disease Outcome and Drug Efficacy

被引：124

作者：

Cowey, C. Lance ^{[1
]}

Rathmell, W. Kimryn ^{[1
]}

机构：

[1] Lineberger Canc Ctr, Chapel Hill, NC 27599 USA

来源：

CURRENT ONCOLOGY REPORTS | 2009年 / 11卷 / 02期

关键词：

TUMOR-SUPPRESSOR GENE; HIPPEL-LINDAU GENE; ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE GENES; SOMATIC MUTATIONS; INTERFERON-ALPHA; CANCER; IDENTIFICATION; PROGNOSIS; THERAPY;

D O I：

10.1007/s11912-009-0015-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The therapeutic landscape for renal cell carcinoma (RCC) has changed drastically over the past several years with the emergence of molecularly targeted therapies. With previous prognostic and predictive tools based on studies of patients treated with cytokine therapies, confirmation of these prior methods and discovery of new markers in this new era of targeted therapy are of great importance. Alteration of the von Hippel-Lindau gene (VHL) by mutation, loss of heterozygosity, and promoter methylation has been found to be important to RCC pathogenesis. In this review, we discuss the potential role of VHL mutation as a prognostic and predictive marker for RCC.

引用

页码：94 / 101

页数：8

共 48 条

[41] VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma [J].